Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519864
rs1057519864
AR
0.030 GeneticVariation BEFREE Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR. 27276681

2016
dbSNP: rs1057519864
rs1057519864
AR
0.030 GeneticVariation BEFREE The consequence of suppressing AR-F876L may then abrogate AR-F876L mediated CRPC cell proliferation and metastasis. 27233475

2016
dbSNP: rs1057519864
rs1057519864
AR
0.030 GeneticVariation BEFREE AR F876L is sufficient to confer resistance to ARN-509 and enzalutamide in in vitro and in vivo models of castration-resistant prostate cancer (CRPC). 23779130

2013